Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2021 | May 04, 2021 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0000086115 | |
Entity Registrant Name | SAFEGUARD SCIENTIFICS INC | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2021 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2021 | |
Document Transition Report | false | |
Entity File Number | 1-5620 | |
Entity Incorporation, State or Country Code | PA | |
Entity Tax Identification Number | 23-1609753 | |
Entity Address, Address Line One | 150 N. Radnor Chester Road | |
Entity Address, City or Town | Radnor | |
Entity Address, State or Province | PA | |
Entity Address, Postal Zip Code | 19087 | |
City Area Code | 610 | |
Local Phone Number | 293-0600 | |
Title of 12(b) Security | common stock, par value $0.10 | |
Trading Symbol | SFE | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Small Business | true | |
Entity Filer Category | Non-accelerated Filer | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 20,957,572 |
Consolidated Balance Sheets (Cu
Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Current Assets: | ||
Cash and cash equivalents | $ 21,750 | $ 15,601 |
Restricted cash | 25 | 0 |
Prepaid expenses and other current assets | 588 | 462 |
Total current assets | 22,363 | 16,063 |
Property and equipment, net | 1,736 | 1,790 |
Ownership interests and advances | 62,593 | 50,398 |
Other assets | 292 | 784 |
Total Assets | 86,984 | 69,035 |
Current Liabilities: | ||
Accounts payable | 18 | 56 |
Accrued compensation and benefits | 3,045 | 2,677 |
Accrued expenses and other current liabilities | 577 | 410 |
Lease liability - current | 338 | 327 |
Total current liabilities | 3,978 | 3,470 |
Lease liability - non-current | 1,964 | 2,053 |
Other long-term liabilities | 50 | 637 |
Total Liabilities | 5,992 | 6,160 |
Commitments and contingencies (Note 9) | ||
Equity: | ||
Preferred stock, $0.10 par value; 1,000 shares authorized | 0 | 0 |
Common stock, $0.10 par value; 83,333 shares authorized; 21,573 shares issued at March 31, 2021 and December 31, 2020 | 2,157 | 2,157 |
Additional paid-in capital | 807,111 | 807,582 |
Treasury stock, at cost; 630 and 688 shares at March 31, 2021 and December 31, 2020, respectively | (9,237) | (10,200) |
Accumulated deficit | (719,014) | (736,639) |
Accumulated other comprehensive loss | (25) | (25) |
Total Equity | 80,992 | 62,875 |
Total Liabilities and Equity | $ 86,984 | $ 69,035 |
Consolidated Balance Sheets (_2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Preferred stock, par value (in dollars per share) | $ 0.10 | $ 0.10 |
Preferred stock, shares authorized (in shares) | 1,000 | 1,000 |
Common stock, par value (in dollars per share) | $ 0.10 | $ 0.10 |
Common stock, shares authorized (in shares) | 83,333 | 83,333 |
Common stock, shares issued (in shares) | 21,573 | 21,573 |
Treasury stock, shares (in shares) | 630 | 688 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
General and administrative expense | $ 2,463 | $ 3,532 |
Operating loss | (2,463) | (3,532) |
Other income (loss), net | 706 | (3,567) |
Interest income | 53 | 105 |
Equity income (loss), net | 19,329 | (9,014) |
Net income (loss) before income taxes | 17,625 | (16,008) |
Income tax benefit (expense) | 0 | 0 |
Net income (loss) | $ 17,625 | $ (16,008) |
Net income (loss) per share: | ||
Basic (in dollars per share) | $ 0.84 | $ (0.77) |
Diluted (in dollars per share) | $ 0.84 | $ (0.77) |
Weighted average shares used in computing income (loss) per share: | ||
Basic (in shares) | 20,902 | 20,686 |
Diluted (in shares) | 20,930 | 20,686 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Cash Flows from Operating Activities: | ||
Net cash used in operating activities | $ (2,157) | $ (2,551) |
Cash Flows from Investing Activities: | ||
Proceeds from sales of ownership interests | 9,419 | 708 |
Acquisitions of ownership interests | 0 | (1,000) |
Advances and loans to ownership interests | (1,000) | (1,241) |
Net cash provided by (used in) investing activities | 8,419 | (1,533) |
Cash Flows from Financing Activities: | ||
Tax withholdings related to equity-based awards | (88) | (11) |
Net cash used in financing activities | (88) | (11) |
Net change in cash, cash equivalents and restricted cash | 6,174 | (4,095) |
Cash, cash equivalents and restricted cash at beginning of period | 15,601 | 25,053 |
Cash, cash equivalents and restricted cash at end of period | $ 21,775 | $ 20,958 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Treasury Stock [Member] | Total |
Balance at Dec. 31, 2019 | $ (697,223) | $ (25) | $ 2,157 | $ 810,856 | $ (14,024) | $ 101,741 |
Balance (in shares) at Dec. 31, 2019 | 21,573 | 930 | ||||
Net income (loss) | (16,008) | 0 | $ 0 | 0 | $ 0 | (16,008) |
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net | 0 | 0 | $ 0 | (32) | $ 104 | 72 |
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares) | 0 | (6) | ||||
Stock-based compensation expense | 0 | 0 | $ 0 | 3 | $ 0 | 3 |
Balance at Mar. 31, 2020 | (713,231) | (25) | $ 2,157 | 810,827 | $ (13,920) | 85,808 |
Balance (in shares) at Mar. 31, 2020 | 21,573 | 924 | ||||
Balance at Dec. 31, 2020 | (736,639) | (25) | $ 2,157 | 807,582 | $ (10,200) | 62,875 |
Balance (in shares) at Dec. 31, 2020 | 21,573 | 688 | ||||
Net income (loss) | 17,625 | 0 | $ 0 | 0 | $ 0 | 17,625 |
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net | 0 | 0 | $ 0 | (593) | $ 963 | 370 |
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares) | 0 | (58) | ||||
Stock-based compensation expense | 0 | 0 | $ 0 | 122 | $ 0 | 122 |
Balance at Mar. 31, 2021 | $ (719,014) | $ (25) | $ 2,157 | $ 807,111 | $ (9,237) | $ 80,992 |
Balance (in shares) at Mar. 31, 2021 | 21,573 | 630 |
Note 1 - General
Note 1 - General | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. The accompanying unaudited interim Consolidated Financial Statements of Safeguard Scientifics, Inc. (“Safeguard” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statement rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are not 10 10 2020 10 Liquidity As of March 31, 2021 In January 2018, not may The Company believes that its cash and cash equivalents at March 31, 2021 one Principles of Accounting for Ownership Interests The Company accounts for its ownership interests using one In addition to holding voting and non-voting equity, the Company also periodically makes advances to its companies in the form of promissory notes which are included in the Ownership interests and advances on the Consolidated Balance Sheets. Equity Method. not not 20% 50% not one When the Company’s carrying value in an equity method company is reduced to zero, the Company records no not not Other Method. not not Impairment of Ownership Interests and Advances On a periodic basis, but no not Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value. The estimated fair value of privately held companies is generally determined based on the value at which independent third Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations. The reduced cost basis of a previously impaired company accounted for using the Equity method is not |
Note 2 - Ownership Interests an
Note 2 - Ownership Interests and Advances | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Investments in and Advances to Affiliates, Schedule of Investments [Text Block] | 2. The following summarizes the carrying value of the Company’s ownership interests and advances. March 31, 2021 December 31, 2020 (Unaudited - In thousands) Equity Method: Companies $ 27,541 $ 27,550 Private equity funds 271 271 27,812 27,821 Other Method: Companies 32,833 19,683 Private equity funds 268 268 33,101 19,951 Advances to companies 1,680 2,626 $ 62,593 $ 50,398 During the quarter ended March 31, 2021, not not may third 3 During the quarter ended March 31, 2021, may first no no During the quarter ended March 31, 2021, first no no Summarized Financial Information The following table summarizes the statement of operations data for the companies accounted for under the equity method for the three March 31, 2021 2020 one not Three Months Ended March 31, 2021 2020 (Unaudited - In thousands) Results of Operations: Revenue $ 40,168 $ 47,414 Gross profit $ 28,228 $ 29,506 Net loss $ (23,021 ) $ (14,604 ) |
Note 3 - Acquisitions of Owners
Note 3 - Acquisitions of Ownership Interests | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Cost and Equity Method Investments Disclosure [Text Block] | 3. The following is a summary of additional deployments during the three March 31, 2021 During the quarter ended March 31, 2021, 11% The Company funded an additional $1.0 million of convertible loans to Trice Medical, Inc. The Company had previously deployed an aggregate of $10.8 million. Trice is focused on orthopedic diagnostics using fully integrated camera-enabled technologies to provide clinical solutions to physicians. |
Note 4 - Fair Value Measurement
Note 4 - Fair Value Measurements | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 4. The Company categorizes its financial instruments into a three 1 3 Cash and cash equivalents and accounts payable approximate fair value due to their short term nature. The Company did not 2 3 March 31, 2021 December 31, 2020. |
Note 5 - Stock-based Compensati
Note 5 - Stock-based Compensation | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 5. Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows: Three Months Ended March 31, 2021 2020 (Unaudited - In thousands) General and administrative expense $ 245 $ 86 $ 245 $ 86 During the three March 31, 2021 2020 |
Note 6 - Income Taxes
Note 6 - Income Taxes | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 6. The Company recorded no consolidated income tax benefit (expense) for the three March 31, 2021 2020 not three March 31, 2021 three March 31, 2021 no |
Note 7 - Net Income (Loss) Per
Note 7 - Net Income (Loss) Per Share | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 7. The calculations of net income (loss) per share were as follows: Three Months Ended March 31, 2021 2020 (Unaudited - In thousands, except per share data) Basic: Net income (loss) $ 17,625 $ (16,008 ) Weighted average common shares outstanding 20,902 20,686 Net income (loss) per share $ 0.84 $ (0.77 ) Diluted: Net income (loss) for dilutive share computation $ 17,625 $ (16,008 ) Number of shares used in basic per share computation 20,902 20,686 Unvested restricted stock and DSU's 28 — Employee stock options — — Weighted average common shares outstanding 20,930 20,686 Net income (loss) per dilutive share $ 0.84 $ (0.77 ) Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs). If an equity method company has dilutive stock options, unvested restricted stock, DSUs or warrants, diluted net income (loss) per share is computed by first Diluted earnings per share do not • At March 31, 2021 2020 • At March 31, 2021 2020 |
Note 8 - Segment Reporting
Note 8 - Segment Reporting | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 8. The Company operates as one operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources. As of March 31, 2021 9 Certain of the Company’s ownership interests as of March 31, 2021 Company Name Safeguard Primary Ownership as of March 31, 2021 Accounting Method Aktana, Inc. 15.0% Equity Bright Health Group * Other Clutch Holdings, Inc. 42.3% Equity Flashtalking 13.2% Other InfoBionic, Inc. 25.2% Equity Lumesis, Inc. 43.4% Equity MediaMath, Inc. 13.3% Other meQuilibrium 32.0% Equity Moxe Health Corporation 27.6% Equity Prognos Health Inc. 28.5% Equity Syapse, Inc. 11.1% Equity Trice Medical, Inc. 16.6% Equity *not As of March 31, 2021 December 31, 2020 |
Note 9 - Commitments and Contin
Note 9 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 9. In March 2019, June 2019. April 2026, A summary of the Company's operating lease cash flows at March 31, 2021 Operating lease payments Expected sublease receipts (Unaudited - In thousands) 2021 (nine months ending December 31) $ 447 $ 396 2022 601 540 2023 607 556 2024 613 573 2025 619 590 2026 207 199 Thereafter — — Total future minimum lease payments 3,094 $ 2,854 Less imputed interest (792 ) Total operating lease liabilities $ 2,302 The Company and the companies in which it holds ownership interests are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, it is not no one The Company had outstanding guarantees of $3.8 million at March 31, 2021 one In 2018, February 2019 June 2020, January 2018. June 2020 first may first first no second 60 March 31, 2021 The Company recorded severance expense for certain employees of $0.8 million during the three March 31, 2021 three March 31, 2021, second 2021. March 31, 2021 In June 2011, March 2012, July 2015 one 2014 one |
Note 10 - Equity
Note 10 - Equity | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 10. In July 2015, not 2020 three March 31, 2021 |
Note 11 - Subsequent Event
Note 11 - Subsequent Event | 3 Months Ended |
Mar. 31, 2021 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 11. In April 2021, may 12 In May 2021, 10b5 1 10b 18 1934, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Liquidity, Policy [Policy Text Block] | Liquidity As of March 31, 2021 In January 2018, not may The Company believes that its cash and cash equivalents at March 31, 2021 one |
Investment, Policy [Policy Text Block] | Principles of Accounting for Ownership Interests The Company accounts for its ownership interests using one In addition to holding voting and non-voting equity, the Company also periodically makes advances to its companies in the form of promissory notes which are included in the Ownership interests and advances on the Consolidated Balance Sheets. Equity Method. not not 20% 50% not one When the Company’s carrying value in an equity method company is reduced to zero, the Company records no not not Other Method. not not Impairment of Ownership Interests and Advances On a periodic basis, but no not Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value. The estimated fair value of privately held companies is generally determined based on the value at which independent third Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations. The reduced cost basis of a previously impaired company accounted for using the Equity method is not |
Note 2 - Ownership Interests _2
Note 2 - Ownership Interests and Advances (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block] | March 31, 2021 December 31, 2020 (Unaudited - In thousands) Equity Method: Companies $ 27,541 $ 27,550 Private equity funds 271 271 27,812 27,821 Other Method: Companies 32,833 19,683 Private equity funds 268 268 33,101 19,951 Advances to companies 1,680 2,626 $ 62,593 $ 50,398 |
Equity Method Investments [Table Text Block] | Three Months Ended March 31, 2021 2020 (Unaudited - In thousands) Results of Operations: Revenue $ 40,168 $ 47,414 Gross profit $ 28,228 $ 29,506 Net loss $ (23,021 ) $ (14,604 ) |
Note 5 - Stock-based Compensa_2
Note 5 - Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Share-based Payment Arrangement, Activity [Table Text Block] | Three Months Ended March 31, 2021 2020 (Unaudited - In thousands) General and administrative expense $ 245 $ 86 $ 245 $ 86 |
Note 7 - Net Income (Loss) Pe_2
Note 7 - Net Income (Loss) Per Share (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended March 31, 2021 2020 (Unaudited - In thousands, except per share data) Basic: Net income (loss) $ 17,625 $ (16,008 ) Weighted average common shares outstanding 20,902 20,686 Net income (loss) per share $ 0.84 $ (0.77 ) Diluted: Net income (loss) for dilutive share computation $ 17,625 $ (16,008 ) Number of shares used in basic per share computation 20,902 20,686 Unvested restricted stock and DSU's 28 — Employee stock options — — Weighted average common shares outstanding 20,930 20,686 Net income (loss) per dilutive share $ 0.84 $ (0.77 ) |
Note 8 - Segment Reporting (Tab
Note 8 - Segment Reporting (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Schedule of Partner Company Ownership Interest [Table Text Block] | Company Name Safeguard Primary Ownership as of March 31, 2021 Accounting Method Aktana, Inc. 15.0% Equity Bright Health Group * Other Clutch Holdings, Inc. 42.3% Equity Flashtalking 13.2% Other InfoBionic, Inc. 25.2% Equity Lumesis, Inc. 43.4% Equity MediaMath, Inc. 13.3% Other meQuilibrium 32.0% Equity Moxe Health Corporation 27.6% Equity Prognos Health Inc. 28.5% Equity Syapse, Inc. 11.1% Equity Trice Medical, Inc. 16.6% Equity |
Note 9 - Commitments and Cont_2
Note 9 - Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Operating lease payments Expected sublease receipts (Unaudited - In thousands) 2021 (nine months ending December 31) $ 447 $ 396 2022 601 540 2023 607 556 2024 613 573 2025 619 590 2026 207 199 Thereafter — — Total future minimum lease payments 3,094 $ 2,854 Less imputed interest (792 ) Total operating lease liabilities $ 2,302 |
Note 1 - General (Details Textu
Note 1 - General (Details Textual) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Cash and Cash Equivalents, at Carrying Value, Ending Balance | $ 21,750 | $ 15,601 |
Note 2 - Ownership Interests _3
Note 2 - Ownership Interests and Advances (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Dec. 31, 2020 | |
Equity Securities without Readily Determinable Fair Value, Amount | $ 33,101 | $ 19,951 |
Preferred Equity in Acquiror in Connection with Sale of Zipnosis, Inc [Member] | ||
Equity Securities without Readily Determinable Fair Value, Amount | 15,300 | |
Zipnosis [Member] | ||
Proceeds from Sale of Equity Method Investments | 3,300 | |
Equity Method Investment, Realized Gain (Loss) on Disposal, Total | 17,000 | |
WebLinc, Inc. [Member] | ||
Proceeds from Sale of Equity Method Investments | 3,200 | |
Equity Method Investment, Realized Gain (Loss) on Disposal, Total | $ (500) | |
Disposal Group, Including Discontinued Operation, Period of Contingent Proceeds (Month) | 24 months | |
T-Rex Group, Inc [Member] | ||
Proceeds From Sale of Other Method Investment | $ 3,000 | |
Other Method Investment, Gain (Loss) | $ 700 |
Note 2 - Ownership Interests _4
Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Equity Method Companies | $ 27,812 | $ 27,821 |
Other Companies | 33,101 | 19,951 |
Advances to companies | 1,680 | 2,626 |
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total | 62,593 | 50,398 |
Partnership Interest [Member] | ||
Equity Method Companies | 27,541 | 27,550 |
Other Companies | 32,833 | 19,683 |
Private Equity Funds [Member] | ||
Equity Method Companies | 271 | 271 |
Other Companies | $ 268 | $ 268 |
Note 2 - Ownership Interests _5
Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) - Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Revenue | $ 40,168 | $ 47,414 |
Gross profit | 28,228 | 29,506 |
Net loss | $ (23,021) | $ (14,604) |
Note 3 - Acquisitions of Owne_2
Note 3 - Acquisitions of Ownership Interests (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Dec. 31, 2020 | |
Equity Method Investments | $ 27,812 | $ 27,821 |
Syapse, Inc. [Member] | ||
Equity Method Investment, Dilution Gain | $ 7,300 | |
Equity Method Investment, Ownership Percentage | 11.10% | |
Trice Medical [Member] | ||
Convertible Bridge Loan | $ 1,000 | |
Equity Method Investments | 10,800 | |
Syapse, Inc. [Member] | ||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 68,000 |
Note 5 - Stock-based Compensa_3
Note 5 - Stock-based Compensation (Details Textual) - shares shares in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Restricted Stock [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period (in shares) | 11 | 7 |
Note 5 - Stock-based Compensa_4
Note 5 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Stock-based compensation expense | $ 245 | $ 86 |
General and Administrative Expense [Member] | ||
Stock-based compensation expense | $ 245 | $ 86 |
Note 6 - Income Taxes (Details
Note 6 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Income Tax Expense (Benefit), Total | $ 0 | $ 0 |
Note 7 - Net Income (Loss) Pe_3
Note 7 - Net Income (Loss) Per Share (Details Textual) - $ / shares shares in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Share-based Payment Arrangement, Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 45 | 179 |
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share) | $ 10.37 | $ 10.37 |
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share) | $ 17.11 | $ 18.45 |
Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 300 | 300 |
Note 7 - Net Income (Loss) Pe_4
Note 7 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Basic: | ||
Net income (loss) | $ 17,625 | $ (16,008) |
Basic (in shares) | 20,902 | 20,686 |
Basic (in dollars per share) | $ 0.84 | $ (0.77) |
Diluted: | ||
Net income (loss) | $ 17,625 | $ (16,008) |
Basic (in shares) | 20,902 | 20,686 |
Unvested restricted stock and DSU's (in shares) | 28 | 0 |
Employee stock options (in shares) | 0 | 0 |
Diluted (in shares) | 20,930 | 20,686 |
Diluted (in dollars per share) | $ 0.84 | $ (0.77) |
Note 8 - Segment Reporting (Det
Note 8 - Segment Reporting (Details Textual) | 3 Months Ended |
Mar. 31, 2021 | |
Number of Operating Segments | 1 |
Note 8 - Segment Reporting - Sc
Note 8 - Segment Reporting - Schedule of Active Partner Companies by Segment (Details) | Mar. 31, 2021 |
Aktana, Inc. [Member] | |
Ownership Interest | 15.00% |
Clutch Holdings [Member] | |
Ownership Interest | 42.30% |
Flashtalking, Inc. [Member] | |
Ownership Interest | 13.20% |
InfoBionic, Inc. [Member] | |
Ownership Interest | 25.20% |
Lumesis, Inc. [Member] | |
Ownership Interest | 43.40% |
MediaMath, Inc. [Member] | |
Ownership Interest | 13.30% |
meQuilibrium [Member] | |
Ownership Interest | 32.00% |
Moxe Health Corporation [Member] | |
Ownership Interest | 27.60% |
Prognos Health, Inc. [Member] | |
Ownership Interest | 28.50% |
Syapse, Inc. [Member] | |
Ownership Interest | 11.10% |
Trice Medical, Inc. [Member] | |
Ownership Interest | 16.60% |
Note 9 - Commitments and Cont_3
Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |
Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | |
Deferred Compensation Liability, Current and Noncurrent, Total | $ 2 | ||
Supplemental Unemployment Benefits, Severance Benefits | 0.6 | ||
Employee and Severance Agreement, Maximum Aggregate Exposure | 0.9 | ||
Employee Severance [Member] | |||
Restructuring Charges, Total | 0.8 | ||
Payments for Postemployment Benefits | $ 0.4 | ||
Employee Severance [Member] | Forecast [Member] | |||
Payments for Postemployment Benefits | $ 0.4 | ||
Minimum [Member] | |||
Long-term Incentive Plan, Bonus Pool Percent | 0.20% | 1.00% | |
Maximum [Member] | |||
Long-term Incentive Plan, Bonus Pool Percent | 1.30% | ||
Private Equity Funds [Member] | |||
Guarantor Obligations, Current Carrying Value | $ 3.8 |
Note 9 - Commitments and Cont_4
Note 9 - Commitments and Contingencies - Operating Lease Cash Flow (Details) $ in Thousands | Mar. 31, 2021USD ($) |
2021 (nine months ending December 31), Operating lease payments | $ 447 |
2021 (nine months ending December 31), Expected sublease receipts | 396 |
2022, Operating lease payments | 601 |
2022), Expected sublease receipts | 540 |
2023, Operating lease payments | 607 |
2023), Expected sublease receipts | 556 |
2024, Operating lease payments | 613 |
2024), Expected sublease receipts | 573 |
2025, Operating lease payments | 619 |
2025), Expected sublease receipts | 590 |
2026, Operating lease payments | 207 |
2026), Expected sublease receipts | 199 |
Thereafter, Operating lease payments | 0 |
Thereafter, Expected sublease receipt | 0 |
Total future minimum lease payments, Operating lease payments | 3,094 |
Total future minimum lease payments, Expected sublease receipt | 2,854 |
Less imputed interest, Operating lease payments | (792) |
Total operating lease liabilities, Operating lease payments | $ 2,302 |
Note 10 - Equity (Details Textu
Note 10 - Equity (Details Textual) - USD ($) shares in Thousands, $ in Millions | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Dec. 31, 2020 | Jul. 31, 2015 | |
Stock Repurchase Program, Authorized Amount | $ 25 | ||
Treasury Stock, Shares, Acquired (in shares) | 0 | 0 |
Note 11 - Subsequent Event (Det
Note 11 - Subsequent Event (Details Textual) - USD ($) $ in Millions | 1 Months Ended | ||
Apr. 30, 2021 | May 07, 2021 | Jul. 31, 2015 | |
Stock Repurchase Program, Authorized Amount | $ 25 | ||
Subsequent Event [Member] | |||
Stock Repurchase Program, Authorized Amount | $ 6 | ||
Velano Vascular [Member] | Subsequent Event [Member] | |||
Proceeds From Sale of Other Method Investment | $ 3.4 |